These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9489130)

  • 1. Immunoregulatory properties of type-I interferons: relevance to multiple sclerosis and the hypereosinophilic syndrome.
    Bartholomé EJ; Roufosse FE
    Acta Clin Belg; 1997; 52(6):350-9. PubMed ID: 9489130
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical trial of natural alpha interferon in multiple sclerosis.
    Knobler RL; Panitch HS; Braheny SL; Sipe JC; Rice GP; Huddlestone JR; Francis GS; Hooper CJ; Kamin-Lewis RM; Johnson KP
    Ann N Y Acad Sci; 1984; 436():382-8. PubMed ID: 6398020
    [No Abstract]   [Full Text] [Related]  

  • 3. [Multiple sclerosis; current developments in the pathogenesis and treatment].
    van Lambalgen R; Sanders EA
    Ned Tijdschr Geneeskd; 1984 Sep; 128(35):1669-73. PubMed ID: 6207446
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of multiple sclerosis with various interferons: the cons.
    Johnson KP
    Neurology; 1988 Jul; 38(7 Suppl 2):62-5. PubMed ID: 3133576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What is the relevance of the various immunomodulatory effects of interferons?
    Morris A
    Ann Inst Pasteur Immunol (1985); 1985; 136D(1):79-81. PubMed ID: 2415043
    [No Abstract]   [Full Text] [Related]  

  • 6. Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome.
    Cogan E; Schandené L; Crusiaux A; Cochaux P; Velu T; Goldman M
    N Engl J Med; 1994 Feb; 330(8):535-8. PubMed ID: 8302319
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunosuppressive effects of recombinant interferon-alpha during long-term treatment of cancer patients.
    Teichmann JV; Sieber G; Ludwig WD; Ruehl H
    Cancer; 1989 May; 63(10):1990-3. PubMed ID: 2702571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural killer cell activity in patients with multiple sclerosis given alpha interferon.
    Rice GP; Casali P; Merigan TC; Oldstone MB
    Ann Neurol; 1983 Sep; 14(3):333-8. PubMed ID: 6638954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Th2 lymphocytes in man: a new cause of hypereosinophilic syndrome].
    Goldman M
    Bull Mem Acad R Med Belg; 2000; 155(1-2):141-5; discussion 145-6. PubMed ID: 11048401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Interferon therapy in multiple sclerosis. Mechanism of action, side effects, results].
    Huber M
    Nervenarzt; 1988 Sep; 59(9):514-20. PubMed ID: 2460777
    [No Abstract]   [Full Text] [Related]  

  • 11. Alpha-interferon. Its effect upon lymphocyte subpopulations and HLA-DR expression within the liver.
    Yoo YK; Gavaler JS; Chen KN; Dindzans V; Brouillette DE; Whiteside TL; Van Thiel DH
    Dig Dis Sci; 1989 Nov; 34(11):1758-64. PubMed ID: 2531067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of recombinant alpha 2-interferon on defective natural killer cell activity in multiple sclerosis.
    Hirsch RL; Johnson KP
    Neurology; 1985 Apr; 35(4):597-600. PubMed ID: 3982654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic interferon therapy for multiple sclerosis. Design of a trial.
    Johnson KP
    Arch Neurol; 1983 Oct; 40(11):681-2. PubMed ID: 6194777
    [No Abstract]   [Full Text] [Related]  

  • 14. Interferon in multiple sclerosis.
    Färkkilä M; Iivanainen M
    Clin Neuropharmacol; 1988 Apr; 11(2):120-9. PubMed ID: 2454155
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunology of multiple sclerosis.
    Oger J; Roos R; Antel JP
    Neurol Clin; 1983 Aug; 1(3):655-79. PubMed ID: 6209537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Type I interferons inhibition of inflammatory T helper cell responses in systemic lupus erythematosus.
    Mangini AJ; Lafyatis R; Van Seventer JM
    Ann N Y Acad Sci; 2007 Jun; 1108():11-23. PubMed ID: 17893966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serial immunological studies in multiple sclerosis patients treated systemically with human alpha interferon.
    Panitch HS; Francis GS; Hooper CJ; Merigan TC; Johnson KP
    Ann Neurol; 1985 Oct; 18(4):434-8. PubMed ID: 2416265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-12 family members and type I interferons in Th17-mediated inflammatory disorders.
    Goriely S; Cavoy R; Goldman M
    Allergy; 2009 May; 64(5):702-9. PubMed ID: 19383026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Killer-helper effect of L cells in the generation of anti-MM cytotoxic T lymphocytes: replacement by beta-interferon and mechanisms of action.
    Ishikawa S; Tachibana T
    Jpn J Cancer Res; 1986 Sep; 77(9):931-40. PubMed ID: 2945807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression of markers of immunocompetent cells, cytokine level, and L-arginine metabolism in complex extremely high frequency and interferon therapy of inflammatory diseases in women of highlands].
    Taradiĭ NN; Bagdasarova IV; Uzdenova ZKh; Bichekueva FKh; Doloman LB; Kotsiuruba AV; Krivokhatskaia LD; Kamenetskaia OV; Mandziuk IaP; Volkova LN
    Fiziol Zh (1994); 2003; 49(3):80-9. PubMed ID: 12918255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.